loops7/E+ via Getty Images
Adamis Pharmaceuticals (ADMP) has been a “Story Stock” a couple of times with its epinephrine product, SYMJEPI, and its naloxone candidate, ZIMHI. SYMJEPI was supposed to be the answer to the notoriously over-priced Epi-Pen by…
Boeing Stock Analysis: Sales Increase 8% to $24.6 Billion. Time to Buy?
September 1, 2026
